Ruxolitinib inhibited STAT3 activation and decreased cell growth in breast cancer[66,67], NSCLC[68], HNC[69], esophageal cancer[70], bladder cancer[71], HCC[72], cervical cancer[73], and colorectal cancer[74,75] cell lines. Here, STAT3 is linked to hepatocellular carcinoma.